Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Yearbook of Cardiology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0145-4145(08)01026-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.

  2007cited by this paper
• Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition

  2006cited by this paper
• Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

  2006cited by this paper
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy

  2006cited by this paper
• Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.

  2004cited by this paper
• Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.

  2004cited by this paper
• Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

  2004cited by this paper
• Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin

  2002cited by this paper
• Potential protective role of angiotensin‐converting enzyme inhibitors captopril and enalapril against adriamycin‐induced acute cardiac and hepatic toxicity in rats

  2001cited by this paper
• Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.

  2000cited by this paper
• Captopril ameliorates myocardial and hematological toxicities induced by adriamycin

  1998cited by this paper

• Managing Doxorubicin Cardiotoxicity: Insights Into Molecular Mechanisms and Protective Strategies

  2025cites this paper
• Is Carvedilol Effective in Preventing and Modulating Concentric Cardiac Remodelling? A Comprehensive Systematic Review and Meta-Analyses

  2025influential citation
• Cardioprotective Diet to Prevent Anthracycline-Induced Cardiotoxicity in Patients with Breast Cancer: A Randomized Open-Label Controlled Trial

  2024cites this paper
• Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors

  2023cites this paper
• Plasma biomarkers reflecting high oxidative stress in the prediction of myocardial injury due to anthracycline chemotherapy and the effect of carvedilol: insights from the CECCY Trial

  2022cites this paper
• Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials

  2022cites this paper
• Choline Protects the Heart from Doxorubicin-Induced Cardiotoxicity through Vagal Activation and Nrf2/HO-1 Pathway

  2022cites this paper
• Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect

  2022cites this paper
• NMCP‐2 polysaccharide purified from Morchella conica effectively prevents doxorubicin‐induced cardiotoxicity by decreasing cardiomyocyte apoptosis and myocardial oxidative stress

  2021cites this paper
• Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies

  2021cites this paper
• Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer

  2021cites this paper
• Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment.

  2021cites this paper
• Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation

  2020cites this paper
• Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis

  2020cites this paper
• Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma

  2020cites this paper
• Personalized Approach to Cancer Treatment–Related Cardiomyopathy

  2020cites this paper
• In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity

  2020cites this paper
• Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring

  2019cites this paper
• Protective effects of S‐carvedilol on doxorubicin‐induced damages to human umbilical vein endothelial cells and rats

  2019cites this paper
• Cardioprotection in cancer therapy: novel insights with anthracyclines

  2019cites this paper
• Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials

  2019influential citation
• Heart failure from cancer therapy: can we prevent it?

  2019cites this paper
• Cardioprotective Approaches to the Management of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Do We Need Increased Surveillance in Elderly Women on Trastuzumab?

  2018cites this paper
• Approaches to the prevention of cardiotoxicity in patients with oncological disease

  2018cites this paper
• Cardio‐Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction

  2017cites this paper
• P-459 Myocardial Changes in Childhood Cancer Patients Treated with Anthracyclines

  2017cites this paper
• Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview

  2017cites this paper
• Cardiac Toxicity of HER2-Directed Therapy in Women with Breast Cancer: Epidemiology, Etiology, Risk Factors, and Management

  2017cites this paper
• From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

  2017cites this paper
• SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy.

  2016cites this paper
• Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

  2016cites this paper
• Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.

  2016cites this paper
• Cancer Cardiotoxicity and Cardiac Biomarkers

  2015cites this paper
• Chemotherapy-induced cardiomyopathy

  2015cites this paper
• Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment

  2015cites this paper
• The European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry: long-term benefits for breast cancer treatment.

  2015cites this paper
• Heart failure and chemotherapeutic agents.

  2015cites this paper
• Mitochondrial Dysfunction on the Toxic Effects of Anticancer Agents— From Lab Bench to Bedside

  2015cites this paper
• Chemotherapy-induced cardiotoxicity: detection, prevention, and management.

  2014influential citation
• Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan

  2013cites this paper
• Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of

  2013influential citation
• Quimioterápicos y cardiotoxicidad: un enfoque actual y práctico para el clínico de una disciplina en pleno desarrollo

  2013cites this paper
• Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors

  2013cites this paper
• Cardiovascular toxicities of cancer chemotherapy.

  2013cites this paper
• Left Ventricular Endocardial Dysfunction in Patients with Preserved Ejection Fraction after Receiving Anthracycline

  2013cites this paper
• Chemotherapy-induced Cardiotoxicity.

  2013cites this paper
• Cardiotoxicity of Cancer Therapeutics: Current Issues in Screening, Prevention, and Therapy

  2013cites this paper
• Cardioprotection during chemotherapy: need for faster transfer of knowledge from cardiology to oncology and role for a cardio-oncologist.

  2013cites this paper
• Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

  2012cites this paper
• Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

  2012cites this paper
• Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy

  2011cites this paper
• Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.

  2011cites this paper
• Anticancer therapy induced cardiotoxicity: review of the literature

  2010cites this paper
• Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice.

  2009cites this paper
• Anthracycline-Induced Cardiomyopathy

  2008cites this paper